Subcutaneous Estrogen Replacement Therapy

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 49, Issue 3, 2004, Pages 139-142

  Jones, Maj Stephen C ^a  

^a KEESLER MEDICAL CENTER   (United States)

Author keywords

Biodegradable implants; Estradiol; Estrogen replacement therapy; Menopause

Indexed keywords

ANDROGEN; ESTRADIOL; ESTROGEN; LEVONORGESTREL; PROGESTERONE; TESTOSTERONE;

ABDOMEN; ADRENERGIC SYSTEM; BIODEGRADABILITY; BLEEDING; BREAST CANCER; BUTTOCK; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SELF ADMINISTRATION; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FIRST PASS EFFECT; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSE; PATIENT COUNSELING; PATIENT SELECTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; UTERUS; VAGINA ATROPHY;

ABSORBABLE IMPLANTS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS;

EID: 1642464949     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Bishop PMF: A clinical experiment in oestrin therapy. BMJ 1938;1:939
2. Baker VL: Alternatives to oral estrogen replacement. Obstet Gynecol Clin North Am 1994;21:271-297
3. Studd J, Magos A: Hormone pellet implantation for the menopause and premenstrual syndrome. Obstet Gynecol Clin North Am 1987;14:229-249
4. Lobo RA, March CM, Goebelsmann U, et al: Subdermal estradiol pellets following hysterectomy and oophorectomy. Am J Obstet Gynecol 1980;138:714-719
5. Panay N, Versi E, Savvas M: A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingooophorectomy. Br J Obstet Gynaecol 2000;107:1012-1016
6. Holland EF, Leather AT, Studd JW: The effect of 25 mg percutaneous estradiol implants on the bone mass of postmenopausal women. Obstet Gynecol 1994;83:43-46
7. Owen EJ, Siddle NC, McGarrigle HT, et al: 25 mg oestradiol implants: The dosage of first choice for subcutaneous oestrogen replacement therapy? Br J Obstet Gynaecol 1992;99:671-675
8. Ganger K, Cust M, Whitehead MI: Symptoms of oestrogen deficiency associated with supraphysiological plasma oestradiol concentrations in women with oestradiol implants. BMJ 1989;299:601-602
9. O'Leary A, Bowen-Simpkins P, Tejura H, et al: Are high levels of oestradiol after implants associated with features of dependence? Br J Obstet Gynaecol 1999;106:960-963
10. Naessen T, Persson I, Thor L, et al: Maintained bone density at advanced ages after long term treatment with low dose oestradiol implants. Br J Obstet Gynaecol 1993;100:454-459
11. Studd JW, Holland EF, Leather AT, et al: The dose-response of percutaneous oestradiol implants on the skeletons of postmenopausal women. Br J Obstet Gynaecol 1994;101:787-791
12. Burger H, Hailes J, Nelson J: Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. BMJ 1987;294:936-937
13. Suhonen SP, Allonen HO, Pekka L: Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995;172:562-567